Paper41769697
Remdesivir in COVID-19: pros and cons.
Rouhana El Feghali Y and 3 others. Front Pharmacol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Remdesivir in COVID-19: pros and cons. Papers, record 41769697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41769697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33128197 | Emerging treatment strategies for COVID-19 infection. | Clin Exp Med | 2021 | https://conductscience.org/library/papers/33128197 | PubMed |
| 2 | 33782830 | Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. | Clin Pharmacokinet | 2021 | https://conductscience.org/library/papers/33782830 | PubMed |
| 3 | 38023628 | Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study. | Ther Clin Risk Manag | 2023 | https://conductscience.org/library/papers/38023628 | PubMed |
| 4 | 36603741 | Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score. | Pulm Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36603741 | PubMed |
| 5 | 41160817 | Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. | N Engl J Med | 2025 | https://conductscience.org/library/papers/41160817 | PubMed |
| 6 | 32468196 | Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. | Drug Saf | 2020 | https://conductscience.org/library/papers/32468196 | PubMed |
| 7 | 35634324 | Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics. | Front Immunol | 2022 | https://conductscience.org/library/papers/35634324 | PubMed |
| 8 | 33856918 | COVID-19 and Cardiovascular Disease: From Bench to Bedside. | Circ Res | 2021 | https://conductscience.org/library/papers/33856918 | PubMed |
| 9 | 32015507 | A pneumonia outbreak associated with a new coronavirus of probable bat origin. | Nature | 2020 | https://conductscience.org/library/papers/32015507 | PubMed |
| 10 | 33674391 | COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. | J Pharmacol Exp Ther | 2021 | https://conductscience.org/library/papers/33674391 | PubMed |
| 11 | 33264556 | Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33264556 | PubMed |
| 12 | 32821939 | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. | JAMA | 2020 | https://conductscience.org/library/papers/32821939 | PubMed |
| 13 | 36149807 | Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program. | J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/36149807 | PubMed |
| 14 | 34358081 | ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34358081 | PubMed |
| 15 | 33802215 | Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33802215 | PubMed |
| 16 | 33795039 | COVID-19 in Adults With Congenital Heart Disease. | J Am Coll Cardiol | 2021 | https://conductscience.org/library/papers/33795039 | PubMed |
| 17 | 36036936 | Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/36036936 | PubMed |
| 18 | 36052127 | Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36052127 | PubMed |
| 19 | 33400058 | Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. | AAPS J | 2021 | https://conductscience.org/library/papers/33400058 | PubMed |
| 20 | 28659436 | Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/28659436 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CES1 | 1066 | PubTator's text mining | https://conductscience.org/library/genes/1066 | NCBI Gene |
| CTSA | 5476 | PubTator's text mining | https://conductscience.org/library/genes/5476 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| SLC47A1 | 55244 | PubTator's text mining | https://conductscience.org/library/genes/55244 | NCBI Gene |
| SLCO1B1 | 10599 | PubTator's text mining | https://conductscience.org/library/genes/10599 | NCBI Gene |
| SLCO1B3 | 28234 | PubTator's text mining | https://conductscience.org/library/genes/28234 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41769697
GET https://conductscience.org/api/papers/v1/41769697/references?page=2